IV and IV/IP chemotherapy as adjuvant treatment in patients with ovarian cancer leads to similar rates of progression free and overall survival after neoadjuvant chemotherapy
Chandler, C.K., Johnson, K., Boisen, M.M., Berger, J., Taylor, S.E., Huang, M.Volume:
145
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2017.03.361
Date:
June, 2017
File:
PDF, 124 KB
english, 2017